The impact of additive or substitutive clinical study design on the negotiated reimbursement for oncology pharmaceuticals after early benefit assessment in Germany [PDF]
Health Economics Review, 2020 Background We analysed the impact of clinical study design for oncological pharmaceuticals on the subsequent price negotiations after early benefit assessment between pharmaceutical companies and the German National Association of Statutory Health ...
C. M. Dintsios, I. Beinhauer
doaj +2 more sources
Patient-reported data informing early benefit assessment of rare diseases in Germany: A systematic review [PDF]
Health Economics Review, 2019 Background Since the implementation of the Regulation on Patient Integration (2003), the Act on the Reorganization of the Pharmaceutical Market (2011), and the Patient Rights Law (2013), the inclusion of patient perspectives has been further anchored in ...
Ana Babac +2 more
doaj +2 more sources
Relevance of indirect comparisons in the German early benefit assessment and in comparison to HTA processes in England, France and Scotland. [PDF]
Health Econ Rev, 2014 Early benefit assessment in Germany under the legislative framework of AMNOG (Arzneimittelmarktneuordnungsgesetz) requires direct comparisons of the new drug with appropriate comparators determined by the Federal Joint Committee (G-BA).
Lebioda A +4 more
europepmc +3 more sources
Alzheimer’s Research & Therapy, 2022 Background The need for preventive therapies that interrupt the progression of Alzheimer’s disease (AD) before the onset of symptoms or when symptoms are emerging is urgent and has spurred the ongoing development of disease-modifying therapies (DMTs) in ...
Sheila Seleri Assunção +7 more
doaj +4 more sources
PP38 Assessment Outcome By Type Of Available Evidence: Retrospective Analysis Of Oncological Early Benefit Assessment Reports [PDF]
Int J Technol Assess Health CareIntroductionFor early benefit assessment in Germany, drugs must be assessed at market entry as to whether they provide an added benefit versus the current standard therapy. This retrospective analysis focuses on assessment reports prepared by the independent Institute for Quality and Efficiency in Health Care (IQWiG).
Goretzko, Jonas +2 more
europepmc +2 more sources
Assessment of the Cost–Benefit Literature on Early Childhood Education for Vulnerable Children
SAGE Open, 2015 Given international interest in evidence-informed early education policy, we sought to interpret what is often a confusing literature on the performance of early childhood education programs.
Kim M. Dalziel +2 more
doaj +2 more sources
Early respiratory diagnosis: benefits of enhanced lung function assessment [PDF]
BMJ Open Respiratory Research, 2021 Introduction The National Health Service for England Long Term Plan identifies respiratory disease as one of its priority workstreams. To assist with earlier and more accurate diagnosis of lung disease they recommend improvement in delivery of quality-assured spirometry.
Sylvester, Karl P +4 more
openaire +4 more sources
Expanding the Role of Early Health Economic Modelling in Evaluation of Health Technologies; Comment on “Problems and Promises of Health Technologies: The Role of Early Health Economic Modeling” [PDF]
International Journal of Health Policy and Management, 2021 In this commentary, we discuss early stage assessments of innovative medical technologies both in terms of methods applied as well as their use in healthcare decision-making.
Carlo Federici, Aleksandra Torbica
doaj +1 more source
Early Assessment of Benefits [PDF]
Deutsches Ärzteblatt international, 2012 In their review article the authors present the results from the licensing studies for two recently approved hepatitis C virus (HCV) protease inhibitors (boceprevir, telaprevir). Both substances were evaluated by Germany’s Institute for Quality and Efficiency in Health Care (IQWiG), which was commissioned by the Federal Joint Committee Gemeinsamer ...
Thomas, Kaiser +3 more
openaire +2 more sources
eLife, 2021 Tuberculous meningitis has high mortality, linked to excessive inflammation. However, adjunctive anti-inflammatory corticosteroids reduce mortality by only 30%, suggesting that inflammatory pathophysiology causes only a subset of deaths.
Laura Whitworth +12 more
doaj +1 more source